Advertisement
Screener

AMARIN CORP PLC\UK (AMRN) Treasury Stock, Common, Shares

2.8 / 5 stars · 68/120 Roast Me

AMARIN CORP PLC\UK Treasury Stock, Common, Shares

AMARIN CORP PLC\UK (AMRN) had Treasury Stock, Common, Shares of 16.20 million shares as of 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure

us-gaap:TreasuryStockCommonShares · last filed 2026-07-29

  • 2026-06-30: Treasury Stock, Common, Shares 16.20M shares.
  • 2026-03-31: Treasury Stock, Common, Shares 15.95M shares.
  • 2025-12-31: Treasury Stock, Common, Shares 13.63M shares.
  • 2025-09-30: Treasury Stock, Common, Shares 13.63M shares.
Period endTreasury Stock, Common, Shares
2026-06-3016.20M shares
10-Q · filed 2026-07-29
2026-03-3115.95M shares
10-Q · filed 2026-04-29
2025-12-3113.63M shares
10-Q · filed 2026-07-29
2025-09-3013.63M shares
10-Q · filed 2025-10-29
2025-06-3013.31M shares
10-Q · filed 2025-07-30
2025-03-3112.48M shares
10-Q · filed 2025-05-07
2024-12-3110.67M shares
10-K · filed 2026-03-02
2024-09-3010.73M shares
10-Q · filed 2024-10-30
2024-06-3010.64M shares
10-Q · filed 2024-07-31
2024-03-3110.53M shares
10-Q · filed 2024-05-01
2023-12-319.32M shares
10-K · filed 2025-03-12
2023-09-309.19M shares
10-Q · filed 2023-11-01
2023-06-308.96M shares
10-Q · filed 2023-08-02
2022-12-317.99M shares
10-K · filed 2024-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Pulmatrix, Inc. (PULM)United States$0.006B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Ernexa Therapeutics Inc. (ERNA)United States$0.006B